- A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Referente scientifico (PI): CUNEO Antonio
Ente finanziatore: BeiGene
Gestione:OspFe
- Promyelocytic leukemia protein (PML) outside the tumor: a new player in the control of inflammation
Referente scientifico (PI): GIORGI Carlotta
Ente finanziatore: ERC (European Research Council)
Gestione:UniFe
Bando: ERC
- Studio ID:6920 - SENTINEL-ENDO-OSPFE. Fattori di rischio associati al fallimento del mapping del linfonodo sentinella in pazienti con diagnosi di tumore dell'endometrio in stadio iniziale: uno studio retrospettivo
Referente scientifico (PI): GRECO Pantaleo
Ente finanziatore: Dipartimento Scienze Mediche, fondi di dipartimento, Università degli studi di Ferrara
Gestione:UniFe
- A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia who have an Inadequate Response to or are Intolerant of Hydroxyurea.
Referente scientifico (PI): CAVAZZINI Francesco
Ente finanziatore: Merck Sharp & Dohme LLC
Gestione:OspFe
- SCREEN4CARE
Referente scientifico (PI): FERLINI Alessandra
Ente finanziatore: Commissione Europea
Gestione:UniFe
Bando: HORIZON 2020
- Extracellular ATP is a key factor in promoting Alzheimer's disease neuroinflammation.
Referente scientifico (PI): GIULIANI Anna Lisa
Ente finanziatore: Cure Alzheimer's Fund
Gestione:UniFe
- Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia
Referente scientifico (PI): CUNEO Antonio
Ente finanziatore: Janssen Research & Development
Gestione:OspFe
- A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
Referente scientifico (PI): CAVAZZINI Francesco
Ente finanziatore: Constellation Pharmaceuticals, Inc.
Gestione:OspFe
- EURO-NMD ERN
Referente scientifico (PI): FERLINI Alessandra
Ente finanziatore: Commissione Europea
Gestione:OspFe
Bando: HORIZON 2020
- A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor
Referente scientifico (PI): CUNEO Antonio
Ente finanziatore: Geron Corporation
Gestione:OspFe
- Ruxolitinib Observational study in Myelofibrosis treated patients in Italy - ROMEI
Referente scientifico (PI): CAVAZZINI Francesco
Ente finanziatore: Novartis Pharma AG
Gestione:OspFe
- A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013, DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
Referente scientifico (PI): CUNEO Antonio
Ente finanziatore: Genmab
Gestione:OspFe
- Post-Authorisation Registry of ELZONRIS (Tagraxofusp) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Referente scientifico (PI): CUNEO Antonio
Ente finanziatore: Stemline Therapeutics, B.V
Gestione:OspFe
- A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)
Referente scientifico (PI): CUNEO Antonio
Ente finanziatore: Janssen Pharmaceutica NV,, AbbVie Inc.,, F. Hoffmann-La Roche Ltd
Gestione:OspFe
- A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Referente scientifico (PI): CUNEO Antonio
Ente finanziatore: Loxo Oncology, Inc.
Gestione:OspFe
- A prospective, open-label, multicenter, randomized phase III trial to compare the efficay and safety of a combined regimen of Obinutuzumab and GDC-0199 (ABT-199) versus Obinutuzumab and Chlorambucil in previously untreated patients with CLL and coexisting medical conditions
Referente scientifico (PI): CUNEO Antonio
Ente finanziatore: Fortrea CAPS Ltd.
Gestione:OspFe
- A single-arm, multicenter, nilotinib treatment-free remission study in patients with BCR-ABL1 positive Chronic Myelogenous Leukemia in chronic phase who have achieved durable minimal residual disease (MRD) status on first line nilotinib treatment
Referente scientifico (PI): CUNEO Antonio
Ente finanziatore: Novartis
Gestione:OspFe
- AFFIRMO (ATRIAL FIBRILLATION INTEGRATED APPROACH IN FRAIL, MULTIMORBID, AND POLYMEDICATED OLDER PEOPLE)
Collaboratore: TREVISAN Caterina
Ente finanziatore: Commissione Europea
Gestione: UniPd
Bando: HORIZON 2020
- SeeMyLife:Holistic mixed approaches to capture the real life of children with Rare Eye Diseases
Collaboratore: SUPPIEJ Agnese
Ente finanziatore: European Joint Program Rare Diseases Comunità europea
Bando: EJP RD JTC 2021
- International Ovarian Tumour Analysis (IOTA) Phase 5
Collaboratore: GRECO Pantaleo
Ente finanziatore: KU Leuven
- Fluid biomarkers of neurodegeneration
Collaboratore: GIULIANI Anna Lisa
Ente finanziatore: Ministero dell'Università e della Ricerca
Bando: PRIN-PNRR
- FILOSOPHY: Studio prospettico, non interventistico sull'efficacia, la sicurezza e gli esiti correlati alla salute in pazienti affetti da artrite reumatoide attiva da moderata a grave trattati con Filgotinib (fase IV)
Collaboratore: GOVONI Marcello
Ente finanziatore: Alfa-Sigma
Gestione: OspFe
- ASTER: Anifrolumab Study for Treatment Effectiveness in the Real World Multi-National, Observational, Post-Launch Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice (fase IV)
Collaboratore: GOVONI Marcello
Ente finanziatore: Astra-Zeneca
Gestione: OspFe
- LAVENDER: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adults with Chronic and/or Subacute Cutaneous Lupus Erythematosus who are Refractory and/or Intolerant to Antimalarial Therapy - D346BC00001 (fase III)
Collaboratore: GOVONI Marcello
Ente finanziatore: Astra-Zeneca
Gestione: OspFe
- BE-EARLY: 219240 - A Phase 4, multicenter, prospective, open-label study describing the efficacy and safety of belimumab administered subcutaneously in adult participants with early systemic lupus erythematosus.
Collaboratore: GOVONI Marcello
Ente finanziatore: GSK
Gestione: OspFe
Bando:
- CVAY736F12302:A randomized, double-blind, placebo-controlled multicenter phase 3 study to evaluate efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus (SIRIUS-SLE 2) (fase III)
Collaboratore: GOVONI Marcello
Ente finanziatore: Novartis
Gestione: OspFe
Bando:
- DAISY: A Multicenter, Randomized, Parallel-group, Double-blind, Two-arm, Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared with Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive with Systemic Sclerosis
Collaboratore: GOVONI Marcello
Ente finanziatore: Astra-Zeneca
Gestione: OspFe
Bando:
- 218224 BLISSc-ILD:Studio di fase 2/3, randomizzato, in doppio cieco, controllato con placebo, con trattamento a gruppi paralleli volto a valutare l'efficacia e la sicurezza di belimumab somministrato sottocute in pazienti adulti affetti da sclerosi sistemica i stadio
Collaboratore: GOVONI Marcello
Ente finanziatore: GSK
Gestione: OspFe
Bando:
- ALLEGORY: STUDIO DI FASE III, RANDOMIZZATO, IN DOPPIO CIECO, CONTROLLATO CON PLACEBO, MULTICENTRICO VOLTO A VALUTARE L'EFFICACIA E LA SICUREZZA DI OBINUTUZUMAB IN PAZIENTI AFFETTI DA LUPUS ERITEMATOSO SISTEMICO
Collaboratore: GOVONI Marcello
Ente finanziatore: Roche
Gestione: OspFe
Bando:
- CAIN457R12301: Studio randomizzato, a gruppi paralleli, in doppio cieco, controllato con placebo, multicentrico di fase 3, per valutare sicurezza ed efficacia di secukinumab 300mg per via sottocutanea versus placebo, in combinazione con terapia steroidea, in pazienti con arterite a cellule giganti
Collaboratore: GOVONI Marcello
Ente finanziatore: Novartis
Gestione: OspFe
Bando:
- Solving the unsolved Rare Diseases
Collaboratore: FERLINI Alessandra
Ente finanziatore: Commissione Europea
Gestione: UniFe
Bando: HORIZON 2020
- Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY (Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms in hematologY)
Collaboratore: RIGOLIN Gian Matteo
Ente finanziatore: AbbVie
Gestione: OspFe
Bando: EU/EFPIA Innovative Medicines Initiative Joint Undertaking HARMONY grant n◦ 116026.
- A Phase 3 Multi-Center, Randomized, Controlled Study to Assess the Safety and Efficacy of Bomedemstat (IMG-7289) versus Best Available Therapy (BAT) in Patients with Essential Thrombocythemia who are Resistant to or Intolerant of Hydroxyurea
Collaboratore: CUNEO Antonio
Ente finanziatore: Merck Sharp & Dohme LLC
Gestione: OspFe
Bando:
